f6k_042314.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
________________
 
FORM 6-K
________________
 
REPORT OF FOREIGN PRIVATE ISSUER
 
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
 
April 23, 2014
________________
 
 
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
 
 
Novo Allé 
DK- 2880, Bagsvaerd 
Denmark
(Address of principal executive offices)
________________
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
 
Form 20-F [X]     
     Form 40-F [  ]
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes [  ]     
      No [X]
 
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
 
 
 
 

Novo Nordisk A/S – Share repurchase programme


Bagsværd, Denmark, 23 April 2014 On 30 January 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.
 
Under the programme initiated 30 January 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 3.6 billion in the period from 30 January 2014 to 29 April 2014.
 
Since the announcement as of 14 April 2014, the following transactions have been made under the programme:
   
   
Number of
B shares
   
Average
purchase price
   
Transaction
value, DKK
 
Accumulated, last announcement
   
12,650,000
           
3,050,944,515
 
14 April 2014
   
240,000
     
229.31
     
55,034,952
 
15 April 2014
   
275,000
     
232.96
     
64,062,653
 
16 April 2014
   
240,000
     
234.75
     
56,339,712
 
22 April 2014
   
260,000
     
242.52
     
63,055,200
 
Accumulated under the programme
   
13,665,000
             
3,289,437,032
 
 
 
With the transactions stated above, Novo Nordisk owns a total of 17,465,901 B shares of DKK 0.20, corresponding to 0.7% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 22 April 2014, Novo Nordisk has repurchased a total of 14,157,995 B shares equal to a transaction value of DKK 3,394,242,839.


Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 38,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.
 

Further information
Media:
 
 
 
 
Anne Margrethe Hauge
+45 4442 3450
amhg@novonordisk.com
Ken Inchausti (US)
+1 609 514 8316
kiau@novonordisk.com
     
Investors:    
Kasper Roseeuw Poulsen
+45 3079 4303
krop@novonordisk.com
Frank Daniel Mersebach +45 3079 0604 fdni@novonordisk.com
Lars Borup Jacobsen +45 3075 3479 lbpj@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Jannick Lindegaard (US)
+1 609 235 8567
jlis@novonordisk.com
 
Novo Nordisk A/S
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
       
   
Company announcement No 26 / 2014
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
 
Date: April 23, 2014
 
NOVO NORDISK A/S
 
Lars Rebien Sørensen,
President and Chief Executive Officer